Two Sigma Securities’s ADC Therapeutics ADCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.6K Buy
+13,578
New +$15.9K ﹤0.01% 1522
2025
Q1
– Sell
-15,048
Closed -$29.9K – 1410
2024
Q4
$29.9K Buy
+15,048
New +$39.4K ﹤0.01% 1252

Other funds holding ADCT

Two Sigma Securities's ADCT Position: Q3 2026 in Review

Two Sigma Securities opened a new position in ADC Therapeutics (ADCT) in Q3 2026: 13,578 shares worth $16.6K. The stake represents ﹤0.01% of the portfolio and ranks #1522 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in ADCT as recently as Q4 2024.

Two Sigma Securities first reported a position in ADCT in Q4 2024 and has held it in 2 quarters since. The position peaked at $29.9K in Q4 2024. 110 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.

  • Two Sigma Securities held 13,578 shares of ADC Therapeutics worth $16.6K as of Q3 2026.
  • ADC Therapeutics was a new Two Sigma Securities position in Q3 2026.
  • ADC Therapeutics made up ﹤0.01% of Two Sigma Securities's portfolio in Q3 2026, its #1522 holding.
  • Two Sigma Securities first reported a position in ADC Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • Two Sigma Securities's ADC Therapeutics position peaked at $29.9K in Q4 2024.
  • 110 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.

Based on Two Sigma Securities's 13F filing for Q3 2026, filed 16 Nov 2026.